EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects

Shiyu Chen, Kun Qian, Rongbin Pan, Jie Yang, Yuexing Ma, Yuqing Xu, Yaohui Ye, Huaan Yuan

RSC Pharmaceutics · 2026

DOI: 10.1039/d6pm00025h ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Shiyu Chen und 7 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cilostazol (CS) can improve chronic atherosclerosis by inhibiting vascular endothelial hyperplasia, inhibiting platelet aggregation, enhancing vasodilation, and reducing plasma triglycerides.

Zitieren

APA

Chen, S., Qian, K., Pan, R., Yang, J., Ma, Y., Xu, Y., Ye, Y., & Yuan, H. (2026). Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects. RSC Pharmaceutics. https://doi.org/10.1039/d6pm00025h

Vancouver

Chen S, Qian K, Pan R, Yang J, Ma Y, Xu Y, et al. Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects. RSC Pharmaceutics. 2026. doi:10.1039/d6pm00025h

BibTeX
@article{Chen2026,
  author = {Chen, Shiyu and Qian, Kun and Pan, Rongbin and Yang, Jie and Ma, Yuexing and Xu, Yuqing and Ye, Yaohui and Yuan, Huaan},
  title = {Cocrystal hydrate of kaempferol–cilostazol, antioxidant, cytotoxicity and lipid accumulation inhibition effects},
  journal = {RSC Pharmaceutics},
  year = {2026},
  doi = {10.1039/d6pm00025h}
}
Kostenlos starten →